Schizophrenics win NHS drugs battle
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.More than 200,000 people with schizophrenia could benefit from newer, more expensive drugs after campaigners won a 10-year battle yesterday to end rationing.
In a ruling hailed as a victory for people with severe mental illness, the NHS's drugs advisory body, the National Institute for Clinical Excellence, said "atypical" antipsychotics should be much more widely available, especially for newly diagnosed schizophrenia.
The newer drugs have fewer side-effects than the older antipsychotics, but because atypicals cost £1,220 per person a year compared with £70 for the older drugs, charities say patients in many areas have been denied the treatment.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments